12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

AP301 regulatory update

Apeptico said FDA and EMA granted Orphan Drug designation to AP301 to treat high altitude pulmonary edema. The product is in Phase IIa...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >